AIMS: Cardiac resynchronization therapy (CRT) is guideline recommended for the treatment of symptomatic heart failure (HF) with reduced left ventricular ejection fraction and prolonged QRS. However, patients with common comorbidities, such as persistent/permanent atrial fibrillation (AF), are often under-represented in clinical trials. METHODS: The Strategic Management to Optimize Response to Cardiac Resynchronization Therapy (SMART) registry (NCT03075215) was a global, multicentre, registry that enrolled de novo CRT implants, or upgrade from pacemaker or implantable cardioverter defibrillator to CRT-defibrillator (CRT-D), using a quadripolar left ventricular lead in real-world clinical practice. The primary endpoint was CRT response between baseline and 12 month follow-up defined as a clinical composite score (CCS) consisting of all-cause mortality, HF-associated hospitalization, New York Heart Association (NYHA) class and quality of life global assessment. RESULTS: The registry enrolled 2035 patients, of which 1558 had completed CCS outcomes at 12 months. The patient cohort was 33.0% female, mean age at enrolment was 67.5 ± 10.4 years and the mean left ventricular ejection fraction was 29.6 ± 7.9%. Notably, there was a high prevalence of mildly symptomatic patients (NYHA class I/II 51.3%), non-left bundle branch block (LBBB) morphology (38.0%), AF (37.2%) and diabetes mellitus (34.7%) at baseline. CCS at 12 months improved in 58.9% (n = 917) of patients; 20.1% (n = 313) of patients stabilized and 21.0% (n = 328) worsened. Several patient characteristics were associated with a lower likelihood of response to CRT including older age, ischaemic aetiology, renal dysfunction, AF, non-LBBB morphology and diabetes. Higher HF hospitalization (P < 0.001) and all-cause mortality (P < 0.001) were observed in patients with AF. These patients also had lower percentages of ventricular pacing than patients in sinus rhythm at baseline and follow-up (P < 0.001, both). A further association between AF and non-LBBB was observed with 81.4% of AF non-LBBB patients experiencing an HF hospitalization compared with 92.5% of non-AF LBBB patients (P < 0.001). Mortality between subgroups was also statistically significant (P = 0.019). CONCLUSIONS: This large, global registry enrolled a CRT-D population with higher incidence of comorbidities that have been historically underrepresented in clinical trials and provides new insight into factors influencing response to CRT. As defined by CCS, 58.9% of patients improved and 20.1% stabilized. Patients with AF had particularly worse clinical outcomes, higher HF hospitalization and mortality rates and lower percentages of ventricular pacing. High incidence of HF hospitalization in patients with AF and non-LBBB in this real-world cohort suggests that ablation may play an important role in increasing future CRT response rates.

AORN Ospedali dei Colli Monaldi Hospital Naples Italy

APHP Paris France

Arrythmia Research Group Jonesboro Arkansas USA

Belfast City Hospital Trust Belfast UK

Boston Scientific Corporation St Paul Minnesota USA

Cardiology Associates of the Delaware Valley Haddon Heights New Jersey USA

Cardiovascular Associates of Mesa Mesa Arizona USA

Cardiovascular Unit Azienda Ospedaliero Universitaria di Ferrara Ferrara Italy

Department of Cardiology and Cardiac Surgery Arrhythmia Unit Navarra Institute for Health Research Clinica Universidad de Navarra Pamplona Spain

Faculty Hospital U sv Anny Brno Czechia

L'Hopital Prive du Confluent Nantes France

Liverpool Heart and Chest Hospital Liverpool UK

Scottish National Advanced Heart Failure Service Golden Jubilee National Hospital Clydebank UK

VA Loma Linda Loma Linda Loma Linda California USA

See more in PubMed

Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845‐1853. doi:10.1056/NEJMoa013168 PubMed DOI

Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, de Marco T, et al. Cardiac‐resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140‐2150. doi:10.1056/NEJMoa032423 PubMed DOI

Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539‐1549. doi:10.1056/NEJMoa050496 PubMed DOI

Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834‐1843. doi:10.1016/j.jacc.2008.08.027 PubMed DOI

Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac‐resynchronization therapy for the prevention of heart‐failure events. N Engl J Med 2009;361:1329‐1338. doi:10.1056/NEJMoa0906431 PubMed DOI

European Heart Rhythm A , European Society of C , Heart Rhythm S , Heart Failure Society of America (HFSA) , American Society of Echocardiography (ASE) , American Heart Association (AHA) , et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow‐up recommendations and management. Heart Rhythm 2012;9:1524‐1576. doi:10.1016/j.hrthm.2012.07.025 PubMed DOI

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599‐3726. doi:10.1093/eurheartj/ehab368 PubMed DOI

Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:176‐182. doi:10.1054/jcaf.2001.25652 PubMed DOI

Singh JP, Fan D, Heist EK, Alabiad CR, Taub C, Reddy V, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. Heart Rhythm 2006;3:1285‐1292. doi:10.1016/j.hrthm.2006.07.034 PubMed DOI

Gold MR, Birgersdotter‐Green U, Singh JP, Ellenbogen KA, Yu Y, Meyer TE, et al. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J 2011;32:2516‐2524. doi:10.1093/eurheartj/ehr329 PubMed DOI PMC

D'Onofrio A, Botto G, Mantica M, Rosa CLA, Occhetta E, Verlato R, et al. Incremental value of larger interventricular conduction time in improving cardiac resynchronization therapy outcome in patients with different QRS duration. J Cardiovasc Electrophysiol 2014;25:500‐506. doi:10.1111/jce.12381 PubMed DOI

D'Onofrio A, Botto G, Mantica M, la Rosa C, Occhetta E, Verlato R, et al. The interventricular conduction time is associated with response to cardiac resynchronization therapy: interventricular electrical delay. Int J Cardiol 2013;168:5067‐5068. doi:10.1016/j.ijcard.2013.07.201 PubMed DOI

Gold MR, Yu Y, Wold N, Day JD. The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm 2017;14:1748‐1755. doi:10.1016/j.hrthm.2017.10.016 PubMed DOI

Brugada J, Delnoy PP, Brachmann J, Reynolds D, Padeletti L, Noelker G, et al. Contractility sensor‐guided optimization of cardiac resynchronization therapy: results from the RESPOND‐CRT trial. Eur Heart J 2017;38:730‐738. doi:10.1093/eurheartj/ehw526 PubMed DOI PMC

Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S, Waggoner AD, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART‐AV) trial: a randomized trial comparing empirical, echocardiography‐guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660‐2668. doi:10.1161/CIRCULATIONAHA.110.992552 PubMed DOI

Birnie D, Lemke B, Aonuma K, Krum H, Lee KLF, Gasparini M, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm 2013;10:1368‐1374. doi:10.1016/j.hrthm.2013.07.007 PubMed DOI

Gold MR, Singh JP, Ellenbogen KA, Yu Y, Wold N, Meyer TE, et al. Interventricular electrical delay is predictive of response to cardiac resynchronization therapy. JACC Clin Electrophysiol 2016;2:438‐447. doi:10.1016/j.jacep.2016.02.018 PubMed DOI

Gold MR, Yu Y, Singh JP, Stein KM, Birgersdotter‐Green U, Meyer TE, et al. The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm 2013;10:988‐993. doi:10.1016/j.hrthm.2013.03.009 PubMed DOI

Singh JP, Berger RD, Doshi RN, Lloyd M, Moore D, Stone J, et al. Targeted left ventricular Lead implantation strategy for non‐left bundle branch block patients: the ENHANCE CRT study. JACC Clin Electrophysiol 2020;6:1171‐1181. doi:10.1016/j.jacep.2020.04.034 PubMed DOI

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population‐based study of 4 million individuals. Lancet 2018;391:572‐580. doi:10.1016/S0140-6736(17)32520-5 PubMed DOI PMC

Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with cardiac‐resynchronization therapy in mild heart failure. N Engl J Med 2014;370:1694‐1701. doi:10.1056/NEJMoa1401426 PubMed DOI

Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac‐resynchronization therapy for mild‐to‐moderate heart failure. N Engl J Med 2010;363:2385‐2395. doi:10.1056/NEJMoa1009540 PubMed DOI

Gardner RS, D'Onofrio A, Mark G, Gras D, Hu Y, Veraghtert S, et al. Real‐world outcomes in cardiac resynchronization therapy patients: design and baseline demographics of the SMART‐registry. ESC Heart Fail 2021;8:1675‐1680. doi:10.1002/ehf2.13192 PubMed DOI PMC

Gold MR, Yu Y, Singh JP, Birgersdotter‐Green U, Stein KM, Wold N, et al. Effect of interventricular electrical delay on atrioventricular optimization for cardiac resynchronization therapy. Circ Arrhythm Electrophysiol 2018;11:e006055. doi:10.1161/CIRCEP.117.006055 PubMed DOI PMC

Krum H, Lemke B, Birnie D, Lee KL, Aonuma K, Starling RC, et al. A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial. Am Heart J 2012;163:747‐752 e741. doi:10.1016/j.ahj.2012.02.007 PubMed DOI

Saba S, Nair D, Ellis CR, Ciuffo A, Cox M, Gupta N, et al. Usefulness of multisite ventricular pacing in nonresponders to cardiac resynchronization therapy. Am J Cardiol 2022;164:86‐92. doi:10.1016/j.amjcard.2021.10.027 PubMed DOI

Zeitler EP, Friedman DJ, Daubert JP, al‐Khatib SM, Solomon SD, Biton Y, et al. Multiple comorbidities and response to cardiac resynchronization therapy: MADIT‐CRT long‐term follow‐up. J Am Coll Cardiol 2017;69:2369‐2379. doi:10.1016/j.jacc.2017.03.531 PubMed DOI PMC

Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H, et al. Predicted benefit of an implantable cardioverter‐defibrillator: the MADIT‐ICD benefit score. Eur Heart J 2021;42:1676‐1684. doi:10.1093/eurheartj/ehaa1057 PubMed DOI PMC

Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K, et al. Investigation of a novel algorithm for synchronized left‐ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm 2012;9:1807‐1814. doi:10.1016/j.hrthm.2012.07.009 PubMed DOI

Lin AC, Biffi M, Exner DV, Johnson WB, Gras D, Hussin A, et al. Long‐term electrical performance of Attain Performa quadripolar left ventricular leads with all steroid‐eluting electrodes: results from a large worldwide clinical trial. Pacing Clin Electrophysiol 2018;41:920‐926. doi:10.1111/pace.13389 PubMed DOI

Forleo GB, Santini L, Giammaria M, Potenza D, Curnis A, Calabrese V, et al. Multipoint pacing via a quadripolar left‐ventricular lead: preliminary results from the Italian registry on multipoint left‐ventricular pacing in cardiac resynchronization therapy (IRON‐MPP). Europace 2017;19:1170‐1177. doi:10.1093/europace/euw094 PubMed DOI PMC

Elliott MK, Mehta VS, Martic D, Sidhu BS, Niederer S, Rinaldi CA. Atrial fibrillation in cardiac resynchronization therapy. Heart Rhythm 2021;O2:784‐795. doi:10.1016/j.hroo.2021.09.003 PubMed DOI PMC

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386:154‐162. doi:10.1016/S0140-6736(14)61774-8 PubMed DOI PMC

Steinberg BA, Wehrenberg S, Jackson KP, Hayes DL, Varma N, Powell BD, et al. Atrioventricular and ventricular‐to‐ventricular programming in patients with cardiac resynchronization therapy: results from ALTITUDE. J Interv Card Electrophysiol 2015;44:279‐287. doi:10.1007/s10840-015-0058-5 PubMed DOI PMC

Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2012;5:566‐570. doi:10.1161/CIRCHEARTFAILURE.112.968867 PubMed DOI

Van Gelder IC, Rienstra M, Bunting KV, Casado‐Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314‐3414. doi:10.1093/eurheartj/ehae176 PubMed DOI

Mustafa U, Atkins J, Mina G, Dawson D, Vanchiere C, Duddyala N, et al. Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: a systematic review and meta‐analysis of observational studies. Open Heart 2019;6:e000937. doi:10.1136/openhrt-2018-000937 PubMed DOI PMC

Yin J, Hu H, Wang Y, Xue M, Li X, Cheng W, et al. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta‐analysis. Clin Cardiol 2014;37:707‐715. doi:10.1002/clc.22312 PubMed DOI PMC

Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF‐CRT mortality trial. Eur Heart J 2021;42:4731‐4739. doi:10.1093/eurheartj/ehab569 PubMed DOI